Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025
TURKU, FI / / June 12, 2025 /
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement
Median overall survival (mOS) of 13.4 months in r/r HR-MDS patients (n=32) treated with bexmarilimab + azacitidine; mOS of 9.3 months in TP53 mutated patients (n=13)
ORR of 85% and cCR of 50% in patients with frontline MDS (n=20)
Deep bone marrow responses demonstrated at all dose levels in frontline MDS and based on the safety and efficacy data of the trial, the recommended phase III bexmarilimab dose is 3 mg/kg
Turku, Finland- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company advancing next-generation immunotherapies, presents detailed phase II data from its ongoing BEXMAB study evaluating bexmarilimab in high-risk myelodysplastic syndromes (HR-MDS) as an oral presentation at the 30th European Hematology Association's (EHA) Congress, taking place in Milan from 12-15 June 2025.
The presentation will be led by Dr. Mika Kontro, Associate Professor at University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Department of Hematology, and will contain detailed results from the study of bexmarilimab, Faron's investigational anti-Clever-1 antibody, in combination with azacitidine for patients with relapsed or refractory (r/r) and frontline or treatment-naïve HR-MDS. These results expand upon those presented at ASCO 2025 and reaffirm the efficacy and safety of bexmarilimab in this difficult-to-treat population.
Strong efficacy data in both r/r HR-MDS and frontline MDS, support advancement into phase III
The BEXMAB study evaluated bexmarilimab (1, 3, or 6 mg/kg weekly in 28-day cycles), a first-in-class monoclonal antibody targeting the Clever-1 receptor, in combination with azacitidine, a standard-of-care hypomethylating agent (HMA). By blocking Clever-1, bexmarilimab reprograms macrophages in the bone marrow, enhancing anti-tumor immunity.
With 80% of patients with r/r HR-MDS (n=32) falling in the very high/high risk category at baseline, the phase II BEXMAB data demonstrated an estimated median overall survival (mOS) of approximately 13.4 months, significantly surpassing historical outcomes of 5-6 months expected under standard of care. A mOS of 9.3 months was observed in patients with the aggressive mTP53 mutation (n=13). Five patients in the r/r HR-MDS group proceeded to stem cell transplant (SCT), the only curative option. Of the non-mTP53 mutated patients mOS has not yet been reached and 15 out of 19 patients are still alive.
Dr. Mika Kontro, MD, PhD, also the principal investigator of the BEXMAB study, said, "The consistent and durable responses observed with bexmarilimab are notable in this patient population. The survival data with bexmarilimab are encouraging for r/r HR-MDS patients, who have limited treatment options after failing HMA therapy."
In an updated analysis compared to the ASCO data, patients with frontline MDS (n=20; 45% with the TP53 mutation), the combination of bexmarilimab with azacitidine demonstrated an ORR of 85% and a cCR of 50%. In those with TP53, the ORR and cCR were 78% and 44%, respectively. In this group too, 7(35%) patients proceeded to SCT (n=5) or are in planning for transplant (n=2). Though bone marrow responses were observed across all dose levels in these patients, the 3 mg/kg appeared to be more favourable at this early stage, indicating the use of this dose for further trials.
Dr. Petri Bono, Chief Medical Officer of Faron, said, "Achieving this milestone underscores our commitment to addressing the urgent needs of MDS patients. These results support ongoing positive and pivotal discussions with regulatory authorities. We are dedicated to advancing bexmarilimab through clinical development into phase III, with the goal of offering new hope to patients suffering from HR-MDS."
Favourable immune activation with 3 mg/kg bexmarilimab dose
According to new data to be presented at EHA, bexmarilimab showed CLEVER-1 target engagement in both blood and bone marrow across all doses with no indication of accumulation with repeated dosing. Favourable activation of both the adaptive and innate immune system indicators was seen in r/r HR-MDS and frontline MDS with 3 mg/kg bexmarilimab and azacitidine. The combination was well-tolerated in all patients with HR-MDS.
The details of the oral presentation are as follows:
Presentation title: Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Results from the Ph1/2 BEXMAB Study
Session: Oral presentation
Presenter: Dr. Mika Kontro, MD, PhD
Date and Time: 15 June 2025 11:00 - 12:15 CEST
Location: Milan, Italy
Abstract no: S178
Faron Pharmaceuticals remains committed to accelerating the clinical development of bexmarilimab for patients with high-risk myeloid malignancies and anticipates initiating preparations for a Phase III registrational trial in the second half of 2025, following discussions with the FDA.
For more information, please contact:
IR Partners, Finland(Media)Riina TuominenKare Laukkanen
+358 44 313 5005riina.tuominen@irpartners.fi+358 50 553 9535 / +44 7 469 766 223kare.laukkanen@irpartners.fi
FINN Partners, US(Media) Alyssa Paldo
+1 847 791-8085 alyssa.paldo@finnpartners.com
Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner
+44 (0) 207 213 0880
Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä
+358 (0)40 555 4727+358 (0)50 553 8990
About BEXMABThe BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.
About bexmarilimabBexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.
About Faron Pharmaceuticals LtdFaron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.
XXXX
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why the Fed and ECB are no longer on the same page
The Federal Reserve on Wednesday is widely expected to hold interest rates steady for the fourth meeting in a row, while the European Central Bank just lowered its rates for the eighth time in a year. The divide has caught the attention of President Trump, who has seized on the gap as he pushes the Fed to lower rates by a full percentage point. He did so again last week as he called central bank chairman Jerome Powell a "numbskull" who has refused to ease policy despite Europe dropping its rates "10 times." "We've done none," Trump added. "Nobody understands.' The two central banks in the US and Europe have diverged as their respective economies move in different directions, impacted not just by tariffs from the Trump administration but other domestic factors. Earlier this month the ECB cut its benchmark interest rate to 2% from 2.25%, the lowest level since early 2023, leaving borrowing costs now more than 2 percentage points lower in Europe than the US. It also signaled it is nearing the end of its rate-cutting cycle. The Fed last cut rates in December 2024, reaching a target range of 4.25%-4.5%, and has yet to cut rates during Trump's second term in office. Read more: How the Fed rate decision affects your bank accounts, loans, credit cards, and investments 'The president is going to keep getting more and more upset about it,' said Wilmington Trust chief economist Luke Tilley. Perhaps the major difference is how the two central banks are viewing inflation. Policymakers in the US hiked their inflation forecasts in the spring as they worried about the ultimate impact of Trump's tariffs on prices — even though the higher expected prices haven't arrived yet. The Fed will offer new forecasts this coming week. In Europe, by contrast, the ECB has been cutting its inflation forecasts and now expects inflation to fall to its target of 2% this year before falling further to 1.6% next year. 'The European Union is cutting because inflation is low and there's a threat to growth," Tilley said. "I say the Fed either should be or will be cutting because inflation is low and there's a threat to growth, but they're holding on a little bit here.' Jeffrey Roach, chief economist for LPL Financial, said the Fed is more likely to remain in 'wait-and-see' mode than the ECB because US consumers are on stronger footing than their European counterparts, giving the Fed the luxury of time before US policymakers have to act. "Relatively stronger consumer demand means US inflation is running a bit hotter than the Euro area," said Roach. "As growth prospects look weaker in the Euro area, the ECB is becoming more dovish as they respond to economic pressures in Europe." ECB president Christine Lagarde has warned that trade tensions could lead to greater volatility and risk aversion in financial markets, which could weigh on demand in Europe and would also act to lower inflation. Most exports to the US face a 10% tariff, and levies could rise to 50% if the European Union and the US don't reach a deal by the White House's July 9 deadline. A fragmentation of global supply chains could also raise inflation by pushing up import prices and adding to capacity constraints in the domestic economy, Lagarde added. Unlike the US, Europe's central bank does not have a dual mandate. The ECB only targets inflation, while the Fed has to maintain both stable prices and maximum employment. Fed Chair Jerome Powell and many of his colleagues this year have repeatedly urged caution and patience on rates, saying they expect Trump's tariffs to push inflation higher and drag down growth, putting the Fed in a challenging spot. But a divide is emerging within the Fed about whether to hold rates steady for some time or get more comfortable about cuts later this year as officials try to determine whether any inflation coming from Trump's tariffs will prove to be longer-lasting. Some policymakers are arguing for "looking through" the impact of the duties as temporary, a stance that would leave the door open for cuts. Many on the rate-setting committee, however, believe there is a risk that inflation from tariffs could become more persistent. 'If we had a good Fed chairman, you would lower rates,' Trump told reporters earlier this week. 'And you know what? If inflation happened in a year from now or two years, let them raise rates.' The president stressed that the US has a lot of debt coming due and lower rates would mean lower interest expense for the US. 'If this guy would lower rates, we get a lower interest rate. It's unbelievable,' said Trump. 'And he's worried about inflation.' The World Bank warned this week that heightened trade tensions and policy uncertainty are expected to drive global growth down to 2.3 percent this year, nearly half a percentage point lower than the rate that had been expected at the start of the year and the slowest pace since 2008 outside of outright global recessions. The international body said turmoil has resulted in growth forecasts being cut in nearly 70% of all economies — across all regions and income groups. However, a global recession is not expected. Dustin Reid, chief strategist for fixed income at Mackenzie Investments, which has $150 billion in assets under management, said he thinks "the ECB may need to go a bit lower" with its rates. "Tariffs are going to be quite challenging for the European Union,' said Reid. On the Fed side, Reid thinks September is in play for a Fed rate cut. 'I do think the labor market data in the US is cracking a bit,' said Reid, adding that he 'would not be surprised" if Powell this coming week keeps "a little bit of an open door [to] at least keep July in play.' Click here for in-depth analysis of the latest stock market news and events moving stock prices
Yahoo
2 hours ago
- Yahoo
Germany sees limited financial leeway on next EU budget, policy paper shows
By Andreas Rinke BERLIN (Reuters) -Germany wants the European Union's next seven-year budget to keep a lid on spending, according to a policy paper seen by Reuters on Saturday, with Berlin arguing members do not have room to boost the scope of their contributions. The German economy, Europe's largest, has contracted for the past two years and forecasts for 2025 are modest. That has dragged on growth in much of the bloc and meant the German government is entering the budget talks cautiously. "For the foreseeable future, member states' financial leeway will remain limited. There is no basis for increasing the (EU budget's) volume relative to GNI (Gross National Income)," the policy paper from the bloc's biggest budget contributor says. A German government source confirmed the paper was sent to Brussels on Thursday. Negotiations are just starting on the next EU budget period from 2028 to 2034, which covers a sum of about 1.2 trillion euros ($1.4 trillion). EU Commission chief Ursula von der Leyen said last month the budget must be more flexible and focused. Budget talks are contentious within the 27-nation EU, pitting the biggest net budget contributors against poorer net beneficiaries and traditional sectors like agriculture against the need to develop cutting-edge new technologies. The German paper said the next budget should reinforce EU security and defence powers as well as competitiveness. "The EU and its member states must assume greater responsibility for security and defence," it said, noting that the budget must continue support for Ukraine. The document also underlined Germany's aversion to jointly issued debt, saying repayments to the so-called Next Generation EU (NGEU) programme, a pandemic recovery scheme financed by jointly backed bonds, should begin as of 2028. "The federal government rejects a perpetuation of this extraordinary and temporary instrument; an extension is legally excluded," it said. ($1 = 0.8657 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 hours ago
- Medscape
Vasodilators Show Severity-Dependent Effects in SSc-ILD
Vasoactive vasodilating drugs (VVDs) have differential effects on the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD), according to a post hoc analysis of prospectively collected data. Prostanoids were associated with protective benefits in patients with mild vasculopathy, while endothelin-receptor antagonists (ERAs) were linked to a lower risk of worsening symptoms in patients with more severe disease. METHODOLOGY: Researchers conducted a post-hoc analysis of prospectively collected data from the European Scleroderma Trials and Research group (EUSTAR) database. The analysis included 2156 patients with SSc-ILD, confirmed by high-resolution CT, with 5996 yearly visits. VVD treatment included ERAs, phosphodiesterase-5 inhibitors, and prostanoids that had been administered for at least 3 months during the study period. Progression outcomes were assessed within intervals of 9-15 months using three definitions: progression A (forced vital capacity [FVC] decline ≥ 10% or FVC decline of 5%-9% with a ≥ 15% decrease in diffusing capacity of the lungs for carbon monoxide [DLCO]), progression B (FVC decline ≥ 5% or DLCO decline ≥ 10%), and progression C (New York Heart Association functional class worsening). TAKEAWAY: A total of 80% of the patients were women, with 51% having diffuse skin involvement and 56.5% being Scl-70 positive. Prostanoids showed a protective association in patients without digital ulcers against progression A (odds ratio [OR], 0.61; 95% CI, 0.46-0.83) and progression B (OR, 0.76; 95% CI, 0.60-0.94) ERAs were linked to a protective effect against New York Heart Association class worsening (OR, 0.42; 95% CI, 0.21-0.86), regardless of digital ulcer presence. Over the median 5.6-year follow-up, VVD exposure had no effect on mortality. IN PRACTICE: "The beneficial effects of VVDs appear to depend on the severity of the vasculopathy, but further studies are needed to confirm the long-term benefits of VVDs in SSc-ILD,' said study author Adela-Cristina Sarbu, MD, of University Hospital Zurich and Bern University Hospital in Switzerland. SOURCE: Sarbu presented abstract OP0003 at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. LIMITATIONS: This is an observational study with long follow-up periods during which there were changes in clinical practice and treatment guidelines. There was high heterogeneity in the study population and missing data, including insufficient data to access radiological progression by high-resolution CT. DISCLOSURES: Sarbu had no financial disclosures or conflicts of interest to report. Some other study authors had financial relationships with many pharmaceutical companies, some of which market VVDs.
